0001022079-22-000110.txt : 20220623 0001022079-22-000110.hdr.sgml : 20220623 20220623160703 ACCESSION NUMBER: 0001022079-22-000110 CONFORMED SUBMISSION TYPE: 11-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220623 DATE AS OF CHANGE: 20220623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 11-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 221035491 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 11-K 1 dgx12312021profitsharingpl.htm 11-K Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 11-K




(Mark One)
x    ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

o    TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______to _______


Commission file number: 001-12215

A. Full title of the plan and the address of the plan, if different from that of the issuer named below:
    

THE QUEST DIAGNOSTICS PROFIT SHARING PLAN (FORMERLY THE PROFIT SHARING PLAN OF QUEST DIAGNOSTICS INCORPORATED)


B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

QUEST DIAGNOSTICS INCORPORATED
500 PLAZA DRIVE
SECAUCUS, NJ 07094




The Quest Diagnostics Profit Sharing Plan
Index to Financial Statements and Supplemental Schedule







Report of Independent Registered Public Accounting Firm

Plan Administrator and Plan Participants
The Quest Diagnostics Profit Sharing Plan    

Opinion on the financial statements
We have audited the accompanying statements of net assets available for benefits of The Quest Diagnostics Profit Sharing Plan (the “Plan”), formerly The Profit Sharing Plan of Quest Diagnostics Incorporated, as of December 31, 2021 and 2020, the related statement of changes in net assets available for benefits for the year ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2021 and 2020, and the changes in net assets available for benefits for the year ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion
These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Supplemental information
The Schedule H, Line 4(i), Schedule of Assets (Held at End of Year) as of December 31, 2021 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan's auditor since 2008.

Boston, Massachusetts
June 23, 2022



1



The Quest Diagnostics Profit Sharing Plan
Statements of Net Assets Available for Benefits
December 31, 2021 and 2020
(in thousands)


20212020
Assets
Cash
$1,282 $— 
Investments, at fair value
5,661,864 4,917,683 
Receivables
Employer contributions receivable1,864 — 
Notes receivable from participants 81,523 97,221 
Investment related receivables3,034 698 
Total assets5,749,567 5,015,602 
Liabilities
Investment related payables582 1,223 
Other liabilities24 1,519 
Total liabilities606 2,742 
Net assets available for benefits
$5,748,961 $5,012,860 





























The accompanying notes are an integral part of these financial statements.
2


The Quest Diagnostics Profit Sharing Plan
Statement of Changes in Net Assets Available for Benefits
For the Year Ended December 31, 2021
(in thousands)


Additions:
Investment Income
Net appreciation in fair value of investments$556,645 
Dividends and interest331,758 
Total investment income888,403 
Interest income on notes receivable from participants5,266 
Contributions
Employer96,990 
Participants200,757 
Total contributions297,747 
Total additions1,191,416 
Deductions:
Benefits paid to participants490,804 
Administrative expenses1,509 
Total deductions492,313 
Net increase699,103 
Net transfer from other plans36,998 
Net assets available for benefits:
Beginning of year5,012,860 
End of year$5,748,961 















The accompanying notes are an integral part of these financial statements.
3


The Quest Diagnostics Profit Sharing Plan
December 31, 2021 and 2020
Notes to Financial Statements (dollars in thousands)



1.    Description of the Plan

    Background - The Quest Diagnostics Profit Sharing Plan (formerly The Profit Sharing Plan of Quest Diagnostics Incorporated) (the “Plan”) is a defined contribution plan. The Plan was established by Quest Diagnostics Incorporated ("Quest Diagnostics" or the "Company"), which is the parent entity of a controlled group of corporations and other entities (the "Quest Control Group"). Effective August 15, 2021, sponsorship of the Plan was transferred from the Company to Quest Diagnostics Clinical Laboratories, Inc. (the "Plan Sponsor"), a wholly owned subsidiary of the Company. The Plan provides retirement benefits to eligible employees of the Quest Control Group. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The following description of the Plan provides only general information. Participants should refer to the plan document for a more complete description of the Plan's provisions.

    Eligibility and Participant Contributions - Eligible employees can participate in the Plan as soon as administratively feasible upon becoming an employee of a member of the Quest Control Group. Participants may contribute an amount between 1% and 35% of their eligible compensation, as defined, for the contribution period. Catch-up contributions, as defined in the Internal Revenue Code (the "Code"), are permissible for eligible participants. Participants may modify their contribution percentage at any time.

    Employer Matching Contributions - Members of the Quest Control Group match 100% of a participant's contribution, up to 5% of eligible compensation, in cash after the participant completes 12 months of service, as defined, with the Quest Control Group. Employer matching contributions are remitted to the Plan at the same time that the corresponding participants' contributions are remitted.

    Participant Accounts - A separate individual account is established for each Plan participant. Each participant's account is credited with the participant's contributions and the employer matching contributions, plus actual earnings thereon. Earnings are allocated by fund based on the ratio of the participant's account invested in a particular fund to all participants' investments in that fund.
    
    Vesting - Participants immediately vest in their voluntary contributions and employer matching contributions plus actual earnings thereon. Certain participants who were active in plans sponsored by previous employers have vesting requirements applied to their previous employer contribution accounts consistent with the vesting requirements in effect before the assets were merged into the Plan.

    Investment Options - Participants may elect to have their voluntary contributions and employer matching contributions invested in any or all of the available investment options, most of which are managed by Fidelity Management & Research Company (“FMRC”). Participants may also elect to have their voluntary contributions and employer matching contributions invested in shares of the Company's common stock through the Quest Diagnostics stock fund. Participants have the ability to modify their investment elections daily, subject to certain short-term trading restrictions imposed by FMRC and the Company's securities trading policy, which prohibits trading in the Company's common stock on a short-term basis and while in possession of material non-public information about the Company.

    Participants cannot contribute greater than 25% per pay period of pre-tax contributions into the Quest Diagnostics stock fund. In addition, participants can transfer monies into the Quest Diagnostics stock fund only to the extent the percentage of holdings in the Quest Diagnostics stock fund after the transfer remains below 25% of the participant's entire account balance.

    Participants may elect to receive their dividends on investments in the Quest Diagnostics stock fund as a taxable cash payment or to have those dividends automatically reinvested.

    Distribution Options - Participants can elect to have their benefit distributions, equal to the value of the vested portion of their account balance, paid in the form of a lump sum distribution, a direct rollover into another eligible retirement plan or traditional individual retirement account, installment payments, or for appropriate assets, an annuity.

    Withdrawals - Withdrawals may be made for qualified emergencies, as defined in the Code. Depending upon the type of withdrawal and the status of the contribution, penalties upon withdrawal may apply. Participants may also begin to make withdrawals without penalty at age 59 ½, subject to certain limitations as defined by the Plan.
4


The Quest Diagnostics Profit Sharing Plan
December 31, 2021 and 2020
Notes to Financial Statements (dollars in thousands) - continued




    Forfeitures - Employer contributions in forfeited nonvested accounts may be used to reduce future employer contributions or pay the Plan's expenses. The forfeiture activity and account balance was not material as of December 31, 2021 and 2020.
        
    Parties-in-Interest - Certain investments of the Plan, as of December 31, 2021 and 2020, are shares of mutual funds and collective funds managed by FMRC. These transactions qualify as party-in-interest transactions.

    The Company also is a party-in-interest to the Plan under the definition provided in Section 3(14) of ERISA. Therefore, Quest Diagnostics stock transactions qualify as party-in-interest transactions. As of December 31, 2021 and 2020, the total fair value of the Plan's investment in Quest Diagnostics stock was $419,743 and $311,954, respectively. During 2021, there were no purchases of Quest Diagnostics stock by the Plan and sales of Quest Diagnostics stock by the Plan were $27,093.

    In addition, the Plan receives revenue sharing credits, as described below, which is considered a party-in-interest transaction.

    Revenue Sharing Credits - A portion of the operating expenses and management fees are paid by the Plan using revenue sharing credits which are included in net appreciation in fair value of investments.  Any amount in excess of the fees is allocated to participant accounts.  Revenue sharing credits earned for the year ended December 31, 2021 were $3,927. During the year ended December 31, 2021, $1,237 of revenue sharing credits were used for permissible management and recordkeeping fees, and $3,822 of revenue sharing credits were allocated to participant accounts. As of December 31, 2021 and 2020, the revenue sharing credit balance was $2,523 and $3,655, respectively.

    Notes Receivable from Participants - Participants are permitted to obtain loans in amounts not less than one thousand dollars and up to the lesser of (1) fifty thousand dollars, subject to certain limitations as defined by the Plan, or (2) 50% of the participant's vested portion of their account value. Except with respect to pre-existing loans transferred or merged into the Plan and as set forth below, a participant may have only one outstanding loan at a time and loans are repayable over a period of up to five years, unless the proceeds are used to purchase a primary residence, in which case a period of up to ten years is permitted. Loans are secured by one-half of a participant's vested account balance and bear interest at prime plus 1%. Rates range from 3.75% to 10.25%; maturities vary by participant. Principal and interest are repaid to the Plan through payroll deductions for active employees. Participants can elect to pay the entire outstanding balance of a loan directly to Fidelity Management Trust Company ("FMTC"). Actively employed participants can also submit a partial loan repayment directly to FMTC outside the normal payroll deductions, accelerating the payoff date. Participants who are no longer active employees may continue to repay outstanding loan balances directly to FMTC.

    During the period from March 27, 2020 through January 31, 2021, participants were permitted to obtain a loan even if the participant had a loan outstanding and the maximum number of loans was increased to two for so long as both such loans are outstanding.

    In addition, notes receivable from participants qualify as party-in-interest transactions. As of December 31, 2021 and 2020, the carrying value of the Plan's notes receivable from participants was $81,523 and $97,221, respectively.

    Plan Administration - The plan administrator is the Benefits Administration Committee (the "Plan Administrator"), which is appointed by the Plan Sponsor's Board of Directors. The Plan's trustee and recordkeeper for the Plan investments are FMTC and Fidelity Investments Institutional Operations Company LLC., respectively.

    Tax Status - The Internal Revenue Service (“IRS”) has determined and informed the Company by letter dated September 22, 2014, that the Plan and related trust are designed in accordance with applicable sections of the Code. The Plan Sponsor believes that the Plan, which has been amended since the IRS determination, continues to be designed and operated in compliance with the applicable requirements of the Code and, therefore, believes that the Plan is qualified and related trust is tax-exempt.

    Accounting principles generally accepted in the United States (“US GAAP”) requires the Plan Administrator to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more likely
5


The Quest Diagnostics Profit Sharing Plan
December 31, 2021 and 2020
Notes to Financial Statements (dollars in thousands) - continued



than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021 and 2020 there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing authorities; however, there are currently no audits for any tax periods in progress.

    Administrative Expenses - Accounting fees and certain administrative expenses of the Plan may be paid by the Plan or the Quest Control Group. Loan origination and certain distribution fees are charged against participant accounts.

    Investment Management Fees - Investment management fees and operating expenses charged to the Plan for investments in the Plan are deducted from income earned on a daily basis and are not separately reflected. Consequently, investment management fees and operating expenses are reflected as a reduction of investment return for such investments.

    Plan Termination - The Plan Sponsor intends to continue the Plan indefinitely, but reserves the right to change or discontinue the Plan at its discretion. Participants will become fully vested in their rights under the Plan if it is terminated or if employer matching contributions are completely discontinued.

    Net Transfer from Other Plans - Following the acquisition of the remaining 56% interest in Mid America Clinical Laboratories, LLC ("MACL") by the Company, Mid America Clinical Laboratories Retirement Savings Plan was merged into the Plan on June 21, 2021.
    
2.    Summary of Significant Accounting Policies

    Basis of Presentation - The Plan maintains its financial records on the accrual basis of accounting.
    
    Use of Estimates - The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, if any, at the date of the financial statements and the reported amounts of additions to and deductions from net assets during the reporting period. Actual results could differ from those estimates.

    Risks and Uncertainties - The Plan provides for participant-directed investment of their voluntary contributions and employer matching contributions in a number of investment funds. Certain underlying investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, changes in these risks could materially affect participants' account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statement of Changes in Net Assets Available for Benefits.

    Benefits paid to participants - Benefits payments to participants are recorded when paid.

    Valuation of Investments - Investments are stated at fair value at year end. Refer to Note 3 for additional information related to the valuation of Plan investments.

    Security Transactions and Income - Purchases and sales of securities are recorded on a trade-date basis. Dividend income is recorded on the ex-dividend date. Interest income from investments is recorded as earned on an accrual basis.

    Net appreciation in fair value of investments represents the Plan's net realized and unrealized gains (losses) on investments held by the Plan.    

    Notes Receivable from Participants - Notes receivable from participants are valued at their unpaid principal balance, plus any accrued but unpaid interest. Interest income from notes receivable from participants is recorded on an accrual basis.     

    Refundable Contributions - The Plan completes non-discrimination testing annually to ensure compliance with the Code. For the years ended December 31, 2021 and 2020, excess contributions determined as a result of the Actual Deferral Percentage test of $24 and $1,519 were netted against participant contributions in the Statement of Changes in Net Assets
6


The Quest Diagnostics Profit Sharing Plan
December 31, 2021 and 2020
Notes to Financial Statements (dollars in thousands) - continued



Available for Benefits, reflected in other liabilities in the Statements of Net Assets Available for Benefits and were paid to Plan in 2022 and 2021, respectively.

3.    Fair Value Measurements

    Fair value measurements are based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, and are determined by either the principal market or the most advantageous market.

    Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.
Level 1:Quoted prices in active markets for identical assets or liabilities.
Level 2:
Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.
Level 3:Valuations derived from valuation techniques in which one or more significant inputs are unobservable.
    
    During the year ended December 31, 2021, certain investments in shares of preferred stock, which were previously classified in Level 3 of the fair value hierarchy, converted into shares of publicly traded common stock, which are now classified within Level 1 of the fair value hierarchy. Excluding this, there was no transfer between levels.

    The following table provides a summary of the assets in the Plan that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
December 31, 2021TotalLevel 1Level 2Level 3
Mutual funds$3,823,016 $3,823,016 $— $— 
Quest Diagnostics common stock419,743 419,743 — — 
Other common stock275,531 272,444 — 3,087 
Preferred stock610 610 — — 
Subtotal$4,518,900 $4,515,813 $— $3,087 
Investments measured at NAV as a practical expedient: (A)1,142,964 
Total investments, at fair value$5,661,864 


7


The Quest Diagnostics Profit Sharing Plan
December 31, 2021 and 2020
Notes to Financial Statements (dollars in thousands) - continued



Basis of Fair Value Measurements
December 31, 2020TotalLevel 1Level 2Level 3
Mutual funds$3,494,729 $3,494,729 $— $— 
Quest Diagnostics common stock311,954 311,954 — — 
Other common stock227,729 227,685 — 44 
Preferred stock1,993 1,250 — 743 
Subtotal$4,036,405 $4,035,618 $— $787 
Investments measured at NAV as a practical expedient: (A)881,278 
Total investments, at fair value$4,917,683 

    
(A)    Certain investments, including the Collective Funds, that were measured at fair value using the net asset value ("NAV") per share (or its equivalent) practical expedient were not classified in the fair value hierarchy. There are no unfunded commitments or redemption restrictions related to these investments.

    Following is a description of the valuation methodologies used for assets measured at fair value. There have been no significant changes in the methodologies used as of December 31, 2021 and 2020.

    Mutual Funds: Valued at the NAV of shares held by the Plan at year end reported on an active market.

    Quest Diagnostics Common Stock, Other Common Stock and Preferred Stock classified as level 1: Valued at the closing price reported on the active market on which the individual securities are traded.

    Other Common Stock and Preferred Stock classified as level 3: Valued using a valuation technique based on available information, which may consider market-based valuation multiples; a discount or premium from market value of a similar, freely traded equity security of the same issuer; or some combination.  These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable.

    Collective Funds: Valued at NAV per unit as determined by the trustee at year end. The NAV is used as a practical expedient to estimate fair value.
        
    The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
    
4.     Commitments and Contingencies

     In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Plan. The complaint alleges, among other things, that the fiduciaries of the Plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. The Plan itself is not named as a defendant. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. In May 2021, the court denied the Company's motion to dismiss the complaint.

        

8


The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333    
    
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2021 (dollars in thousands)

(a)(b)
Identity of Issue, Borrower, Lessor, or Similar Party
(c)
Description
(d)
Cost
(e)
Current
Value
Vanguard Total International Stock Index Fund Institutional SharesMutual Fund***$35,753 
T Rowe Price Government Reserve Investment FundMutual Fund***712 
Vanguard Extended Market Index Fund Institutional SharesMutual Fund***55,182 
Vanguard Total Bond Market Index Fund - Institutional Plus Share ClassMutual Fund***120,310 
MFS Global Equity Fund Class R4Mutual Fund***22,631 
*Fidelity Diversified International Fund Class KMutual Fund***108,894 
*Fidelity Freedom K 2005 FundMutual Fund***6,108 
*Fidelity Freedom K 2010 FundMutual Fund***21,248 
*Fidelity Freedom K 2015 FundMutual Fund***64,627 
*Fidelity Freedom K 2020 FundMutual Fund***223,848 
*Fidelity Freedom K 2025 FundMutual Fund***421,536 
*Fidelity Freedom K 2030 FundMutual Fund***471,038 
*Fidelity Freedom K 2035 FundMutual Fund***386,000 
*Fidelity Freedom K 2040 FundMutual Fund***296,255 
*Fidelity Freedom K 2045 FundMutual Fund***221,694 
*Fidelity Freedom K 2050 FundMutual Fund***140,596 
*Fidelity Freedom K 2055 FundMutual Fund***70,039 
*Fidelity Freedom K 2060 FundMutual Fund***28,365 
*Fidelity Freedom K 2065 FundMutual Fund***3,701 
*Fidelity Freedom K Income FundMutual Fund***16,071 
*Fidelity Puritan Fund Class KMutual Fund***435,101 
*Fidelity 500 Index Fund - Institutional Premium ClassMutual Fund***585,731 
*Fidelity Investments Money Market Government Portfolio - Institutional ClassMutual Fund***87,576 
  Total Interest in Mutual Funds$3,823,016 
*Fidelity Managed Income Portfolio II - Class 3Collective Fund***$230,372 
*Fidelity Contrafund Comingled PoolCollective Fund***383,427 
*Fidelity OTC Comingled PoolCollective Fund***324,290 
GW&K Small/Mid Cap FundCollective Fund***169,903 
Prudential Core Plus Bond Fund Class 5Collective Fund***33,855 
State Street Short Term Investment FundCollective Fund***1,117 
  Total Interest in Collective Funds$1,142,964 
*Quest Diagnostics IncorporatedCommon Stock***$419,743 
9


The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333    
    
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2021 (dollars in thousands)

(a)(b)
Identity of Issue, Borrower, Lessor, or Similar Party
(c)
Description
(d)
Cost
(e)
Current
Value
Abbvie IncOther Common Stock***$1,692 
Advanced Micro Devices IncOther Common Stock***1,353 
Alphabet Inc Cl AOther Common Stock***13,335 
Alphabet Inc Cl COther Common Stock***6,091 
Amazon.Com IncOther Common Stock***13,734 
Ameren CorpOther Common Stock***1,063 
American International GroupOther Common Stock***3,207 
Amphenol Corporation Cl AOther Common Stock***1,988 
Anthem IncOther Common Stock***3,033 
Apple IncOther Common Stock***9,524 
Applied Materials IncOther Common Stock***1,532 
Aptiv PlcOther Common Stock***872 
Asml Hldg Nv (Ny Reg Shs) New York Registered SharOther Common Stock***2,909 
Aurora Innovation Inc Class BOther Common Stock***198 
Avalonbay Communities Inc ReitOther Common Stock***1,179 
Avantor IncOther Common Stock***1,651 
Bank Of America CorporationOther Common Stock***2,172 
Becton Dickinson & CoOther Common Stock***2,985 
Block Inc Cl AOther Common Stock***392 
Boeing CoOther Common Stock***645 
Bunge LimitedOther Common Stock***678 
Carvana Co Cl AOther Common Stock***984 
Centene CorpOther Common Stock***89 
Cf Industries Holdings IncOther Common Stock***1,239 
Chipotle Mexican Grill IncOther Common Stock***1,010 
Chubb LtdOther Common Stock***2,585 
Cigna CorpOther Common Stock***4,730 
Cisco Systems IncOther Common Stock***1,096 
Citigroup IncOther Common Stock***223 
Citrix Systems IncOther Common Stock***875 
Coca Cola CoOther Common Stock***991 
Comcast Corp Cl AOther Common Stock***1,452 
Conagra Brands IncOther Common Stock***854 
ConocophillipsOther Common Stock***1,465 
Costar Group IncOther Common Stock***18 
Coupang Inc AOther Common Stock***669 
Cummins IncOther Common Stock***952 
CVS Health CorpOther Common Stock***1,043 
Disney (Walt) CoOther Common Stock***1,440 
10


The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333    
    
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2021 (dollars in thousands)

(a)(b)
Identity of Issue, Borrower, Lessor, or Similar Party
(c)
Description
(d)
Cost
(e)
Current
Value
Dollar General CorpOther Common Stock***$1,964 
Doordash IncOther Common Stock***220 
Draftkings Inc Cl AOther Common Stock***377 
Elanco Animal Health IncOther Common Stock***634 
Entergy CorpOther Common Stock***808 
Equitable Holdings IncOther Common Stock***1,316 
Exxon Mobil CorpOther Common Stock***1,223 
Farfetch Ltd Cl AOther Common Stock***417 
Fifth Third BancorpOther Common Stock***1,959 
Fiserv IncOther Common Stock***3,540 
Fortinet IncOther Common Stock***2,632 
Fox Corporation BOther Common Stock***362 
General Electric CoOther Common Stock***3,551 
Global Payments IncOther Common Stock***2,336 
Goldman Sachs Group IncOther Common Stock***1,308 
Hashicorp IncOther Common Stock***125 
Hca Healthcare IncOther Common Stock***1,778 
Hologic IncOther Common Stock***932 
Humana IncOther Common Stock***1,315 
Huntington Bancshares IncOther Common Stock***1,032 
Iac/InteractivecorpOther Common Stock***762 
Illinois Tool Works IncOther Common Stock***1,187 
Ingersoll Rand IncOther Common Stock***1,656 
International Flavors & FragraOther Common Stock***1,492 
International Paper CoOther Common Stock***2,106 
Intuit IncOther Common Stock***6,149 
Intuitive Surgical IncOther Common Stock***3,362 
Johnson & JohnsonOther Common Stock***1,810 
Kimberly Clark CorpOther Common Stock***1,360 
Kohls CorpOther Common Stock***525 
Las Vegas Sands CorpOther Common Stock***661 
Live Nation Entertainment IncOther Common Stock***1,023 
Lululemon Athletica IncOther Common Stock***1,155 
Magna Intl IncOther Common Stock***876 
Marketaxess Hldgs IncOther Common Stock***240 
Marsh & Mclennan Cos IncOther Common Stock***1,153 
Mastercard Inc Cl AOther Common Stock***2,045 
Match Group IncOther Common Stock***1,281 
Medtronic PlcOther Common Stock***1,553 
11


The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333    
    
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2021 (dollars in thousands)

(a)(b)
Identity of Issue, Borrower, Lessor, or Similar Party
(c)
Description
(d)
Cost
(e)
Current
Value
Merck & Co Inc NewOther Common Stock***$1,193 
Meta Platforms Inc Cl AOther Common Stock***9,197 
Metlife IncOther Common Stock***2,007 
Microsoft CorpOther Common Stock***21,249 
Mongodb Inc Cl AOther Common Stock***1,415 
Morgan StanleyOther Common Stock***1,191 
Netflix IncOther Common Stock***3,013 
News Corp New Cl AOther Common Stock***980 
Nextera EnergyOther Common Stock***1,339 
Nielsen Holdings PlcOther Common Stock***405 
Nike Inc Cl BOther Common Stock***1,091 
Nvidia CorpOther Common Stock***2,678 
Nxp Semiconductors NvOther Common Stock***705 
Paypal Hldgs IncOther Common Stock***1,173 
Peloton Interactive Inc Cl AOther Common Stock***383 
Perrigo Co PlcOther Common Stock***192 
Pfizer IncOther Common Stock***1,384 
Philip Morris Intl IncOther Common Stock***1,255 
Qualcomm IncOther Common Stock***2,545 
Rivian Automotive IncOther Common Stock***3,835 
Rockwell Automation IncOther Common Stock***695 
Ross Stores IncOther Common Stock***2,528 
S&P Global IncOther Common Stock***1,110 
Salesforce IncOther Common Stock***3,452 
Schwab Charles CorpOther Common Stock***3,096 
Sempra EnergyOther Common Stock***1,759 
Sentinelone IncOther Common Stock***727 
Servicenow IncOther Common Stock***2,580 
Shopify Inc Cl AOther Common Stock***501 
Siemens Ag Spon AdrOther Common Stock***1,089 
Signature BankOther Common Stock***462 
Snap Inc - AOther Common Stock***2,245 
Snowflake Inc Cl AOther Common Stock***153 
Southern CoOther Common Stock***2,789 
Southwest Airlines CoOther Common Stock***695 
Splunk IncOther Common Stock***900 
Spotify Technology SaOther Common Stock***2,131 
Stericycle IncOther Common Stock***745 
12


The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333    
    
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2021 (dollars in thousands)

(a)(b)
Identity of Issue, Borrower, Lessor, or Similar Party
(c)
Description
(d)
Cost
(e)
Current
Value
Stripe Inc Class B PpOther Common Stock***$117 
Stryker CorpOther Common Stock***3,046 
Synopsys IncOther Common Stock***1,702 
Tc Energy CorpOther Common Stock***783 
Te Connectivity LtdOther Common Stock***882 
Tesla IncOther Common Stock***497 
Texas Instruments IncOther Common Stock***1,463 
The Booking Holdings IncOther Common Stock***1,600 
Thermo Fisher Scientific IncOther Common Stock***1,036 
Tjx Companies Inc NewOther Common Stock***1,796 
Totalenergies Se AdrOther Common Stock***2,690 
Tyson Foods Inc Cl AOther Common Stock***1,492 
Uipath Inc AOther Common Stock***676 
United Parcel Service Inc Cl BOther Common Stock***3,170 
Unitedhealth Group IncOther Common Stock***4,411 
Vertex Pharmaceuticals IncOther Common Stock***1,135 
Visa Inc Cl AOther Common Stock***2,914 
Walmart IncOther Common Stock***1,396 
Warner Music Grp Corp Cl AOther Common Stock***344 
Wells Fargo & CoOther Common Stock***4,012 
Welltower IncOther Common Stock***800 
Weyerhaeuser CoOther Common Stock***2,197 
Workday Inc Cl AOther Common Stock***453 
Zimmer Biomet Hldgs IncOther Common Stock***1,316 
Zoom Video Communications Inc Cl AOther Common Stock***543 
  Total Interest in Other Common Stock$275,531 
Becton Dickinson And Co 6.5% PC 06/01/2023Preferred Stock***$216 
Elanco Animal Health Inc 5% PC 02/01/2023Preferred Stock***29 
Southern Company PC 6.75% 08/01/2022Preferred Stock***365 
  Total Interest in Preferred Stock$610 
Investments at Fair Value$5,661,864 
*Notes Receivable from Participants**Loans$81,523 
TOTAL$5,743,387 
*Party-in-interest to the Plan.
**Rates range from 3.75% to 10.25%; maturities vary by participant.
***The cost of participant-directed investments is not required to be disclosed.

13


Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Plan Sponsor of The Quest Diagnostics Profit Sharing Plan has duly caused this annual report to be signed on its behalf by the undersigned, hereunto duly authorized.

June 23, 2022            

The Quest Diagnostics Profit Sharing Plan


By:  /s/ Cecilia K. McKenney
Cecilia K. McKenney
Senior Vice President, Chief Human Resources Officer and Member of the Benefits Administration Committee of Quest Diagnostics Clinical Laboratories, Inc.




14
EX-23 2 dgx12312021ex23-consentfor.htm EX-23 Document

Exhibit 23


Consent of Independent Registered Public Accounting Firm


We have issued our report dated June 23, 2022, with respect to the financial statements and supplemental information included in the Annual Report of The Quest Diagnostics Profit Sharing Plan, formerly The Profit Sharing Plan of Quest Diagnostics Incorporated, on Form 11-K for the year ended December 31, 2021. We consent to the incorporation by reference of said report in the Registration Statement of Quest Diagnostics Incorporated on Form S-8 (File No. 333-157447).

/s/ Grant Thornton LLP
Boston, Massachusetts
June 23, 2022